» Articles » PMID: 8017856

Ifosfamide Metabolism and Pharmacokinetics (review)

Overview
Journal Anticancer Res
Specialty Oncology
Date 1994 Mar 1
PMID 8017856
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

In this article the studies on the pharmacokinetics and metabolism of ifosfamide have been summarised. Ifosfamide is a pro-drug and requires metabolic activation to exert cytotoxic activity. The various metabolites determined after oral or intravenous administration of ifosfamide show a large inter- and intrapatient variability. Oral and intravenous fractionated treatment with ifosfamide exhibits a time-dependent increase in ifosfamide metabolic clearance which is explained by a mechanism of auto-induction of the hepatic oxygenase system. The pharmacokinetic parameters of ifosfamide do not correlate with age, sex and weight. Oral ifosfamide, at a dose higher than 1 g/m2, induces neurotoxicity in a high percentage of patients. In these cases the pharmacokinetics of ifosfamide were not aberrant. This implies that ifosfamide metabolites rather than the parent drug are likely to be responsible for the neurotoxicity. The development of more selective and sensitive analytical methodologies are necessary in order to go in more insight into the disposition of the active ifosfamide metabolites, including their clinical effects. This may lead to a further optimisation of the therapeutic use of ifosfamide.

Citing Articles

Central Nervous System Involvement of Rhabdomyosarcoma: A Single Institution Experience.

Moreira D, Macy M, Cost C, Greffe B, Garrington T J Pediatr Hematol Oncol. 2018; 41(2):152-154.

PMID: 29668538 PMC: 6192856. DOI: 10.1097/MPH.0000000000001166.


Human metabolites and transformation products of cyclophosphamide and ifosfamide: analysis, occurrence and formation during abiotic treatments.

cesen M, Kosjek T, Busetti F, Kompare B, Heath E Environ Sci Pollut Res Int. 2016; 23(11):11209-11223.

PMID: 26920534 DOI: 10.1007/s11356-016-6321-1.


In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

Yaseen Z, Michoudet C, Baverel G, Dubourg L Pediatr Nephrol. 2008; 23(4):611-8.

PMID: 18204866 DOI: 10.1007/s00467-007-0689-6.


Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.

Brunello A, Basso U, Rossi E, Stefani M, Ghiotto C, Marino D Drugs Aging. 2007; 24(11):967-73.

PMID: 17953463 DOI: 10.2165/00002512-200724110-00008.


Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.

Kerbusch T, de Kraker J, Mathjt R, Beijnen J Clin Pharmacokinet. 2001; 40(8):615-25.

PMID: 11523727 DOI: 10.2165/00003088-200140080-00005.